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Abstract
Background: Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that
imposes considerable mortality and it is associated with progressive related disabilities. In this study, we aimed to
assess the effect of the disease across health-related quality of life dimensions, in both carriers of the mutation and
patients, to compare health-related quality of life with general population, as well as to explore health-related
quality of life prognostic factors among patients, including disease progression and treatment.
Methods: This study was a multi-institutional, longitudinal, prospective, observational study of hereditary
Transthyretin Amyloidosis Polyneuropathy Portuguese adult subjects (621 asymptomatic carriers and 733
symptomatic patients) enrolled in the Transthyretin Amyloidosis Outcomes Survey. Health-related quality of life was
captured with the preference-based instrument EQ-5D-3 L. For general population the dataset included all subjects
enrolled in a representative national study (n = 1500). Different econometric models were specified; multivariate
probit, generalized linear model and generalized estimating equations model; including demographic and clinical
covariates.
Results: Hereditary Transthyretin Amyloidosis Polyneuropathy patients have their health status severely impaired in
all quality of life dimensions and more anxiety/depression problems were found among asymptomatic carriers. No
differences on utility were found between carriers and general population (p = 0.209). Among patients, the utility
value is estimated to be 0.51 (0.021), a decrement of 0.27 as compared with general population utility. Higher
disease duration, advanced disease stage and not receiving treatment are associated with impaired health-related
quality of life. No differences were found between genders (p = 0.910) or between late (≥50 years) and early-onset
patients (p = 0.254). The utility estimate ranged from 0.63 (0.009) in stage I to 0.01 (0.005) in stage IV.
Conclusions: Hereditary Transthyretin Amyloidosis Polyneuropathy symptoms and progressive associated disabilities
substantially decrease patient’s health-related quality of life. Clinical strategies focused on health-related quality of life
preservation such as close follow-up of asymptomatic carriers, prompt diagnosis and adequate, early treatment would
benefit patient’s long-term outcomes, slowing the progressive decline in health-related quality of life.
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Background
Hereditary transthyretin amyloid polyneuropathy (hATTR-
PN) is a rare genetic disease, originally described in 1952
by Corino de Andrade in northern Portugal [1]. hATTR-
PN is estimated to affect up to 10,000 people worldwide
[2], the largest cohort of patient being Portuguese [3], al-
most all (> 99% families) carrying the Val30Met mutation
[4]. The disease is related to mutations in the transthyretin
(TTR) gene, leading to deposition of amyloid fibrils in the
peripheral nerves and in vital organs [5]. Most Portuguese
patients have their first symptoms between 28 and 42 years
of age (interquartile range; median 33 years of age) and, if
untreated, the disease progresses fast with the majority of
patients dying within 12 years after disease onset [6].
Disease progression can be staged according to Coutinho
approach [7]. Stage 1 is defined by symptoms primarily
limited to the feet and legs, with pain and temperature sen-
sation more severely impaired than touch, vibration, or
position. Motor involvement is mild, with the patient being
fully ambulatory. Autonomic dysfunction may be present
and may be the presenting symptom, and can cause impo-
tence, urinary retention, and gastrointestinal complications.
In Stage 2 sensory impairment worsens and proceeds prox-
imally, involving the upper limbs. In the lower limbs, touch
sensation is lost. Motor dysfunction worsens, with the pa-
tient requiring assistance to walk with crutches or canes.
Autonomic dysfunction can become more severe and more
difficult to manage. In stage 3, the patient is profoundly af-
fected by both the peripheral and autonomic impairments
and is bedridden or confined to a wheelchair due to gener-
alized weakness and severe cachexia [7].
Currently, two disease modifying treatment are available
in clinical practise for patients in stage 1 (liver transplant-
ation (LTx) since the 90’s [8–10] and tafamidis since 2011
[11, 12]) and two new pharmacologic treatments (inoter-
sen and patisiran) were recently approved for the treat-
ment of adult patients in stage 1 or stage 2 [13, 14].
Although there is significant clinical heterogeneity,
even between patients carrying the same mutation, most
subjects experience neuropathic pain and autonomic
symptoms, such as gastrointestinal, urinary and erectile
dysfunction, and orthostatic hypotension [15]. As the
disease progresses, patients become severely disabled,
malnourished, fatigued, weak, incontinent, bedridden or
bound to a wheelchair, and unable to care for them-
selves [7, 16]. The activities of patients’ daily living be-
came highly affected, leading to considerable emotional
stress, loss of physical condition and independence, as
well as to an increased need for familial, health care and
social support [7, 15]. A recent study found neuropathy-
specific quality of life among hATTR patients nearly
equivalent to that of patients with type 2 diabetes with
diabetic neuropathy accompanied by a history of ulcer-
ation, gangrene, or amputation [17]. Hence hATTR-PN
imposes a considerable and increasing burden to pa-
tients, family and caregivers [18, 19].
In this study, we aimed to assess the effect of hATTR-
PN across Health-Related Quality of Life (HRQoL) di-
mensions, in both carriers and patients, to estimate the
impact of hATTR-PN on utility in comparison to the
general population, as well as to explore HRQoL prog-
nostic factors among patients, including disease progres-
sion and treatment.
Methods
Data
This study was a multi-institutional, longitudinal, observa-
tional study of hATTR-PN Portuguese adult subjects (≥18
years old) enrolled in the Transthyretin Amyloidosis Out-
comes Survey (THAOS). The design and methodology of
THAOS (ClinicalTrials.gov: NCT 00628745) are described
in detail elsewhere [20, 21]. Briefly, THAOS is a prospective
patient’s registry collecting demographic information, dis-
ease characteristics, current and prior treatments, family
history, biopsy results and results of routine measurements
performed in clinical practice, including the preference-
based measure of health, EQ-5D-3L questionnaire.
In our study, the longitudinal follow-up of hATTR-PN
patients was up to 10-years, since THAOS inception
(2007) to study cut-off date (December 31, 2016). Pa-
tients were recruited at either one of the two Portuguese
hATTR-PN referral centers. Data was extracted and vali-
dated at the referral centers, and discrepancies were re-
solved through revision of individual survey records.
Both asymptomatic gene carriers and symptomatic pa-
tients were included. Non-Val30Met subjects and visits
with incomplete EQ-5D-3L data were excluded from the
analysis. For the general population, the dataset included
all subjects enrolled in a representative adult Portuguese
random sample, stratified by region, gender and age
group. The detailed methods and results for the general
population dataset have been described elsewhere [22].
HRQoL was captured with the preference-based in-
strument EQ-5D-3L. This instrument describes an indi-
vidual’s HRQoL using a health classification system
consisting of five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression [23].
Each dimension has three associated severity levels,
where level 1 represents the absence of health problems
and level 3 represents extreme problems. The applica-
tion of a value set to the perceived health state of the re-
spondent generates the EQ-5D-3L index score (utility
value) of the perceived health state [24]. The Portuguese
value set yields an EQ-5D-3L index score that ranges
from − 0.54 (for health states considered worse than
death) to 1.00 (perfect health) [25]. For the general Portu-
guese population, EQ-5D data were collected in a cross-
sectional study [22]. For hATTR-PN subjects, EQ-5D data
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were collected at THAOS enrolment (baseline) and in
subsequent visits during clinical practice (longitudinal
data). The Portuguese value set [25] was used to compute
the EQ-5D-3L index score (utility value) for hATTR-PN
subjects.
Statistical analysis
Two analyses were conducted, making use of the two
different available datasets. In the first analysis, cross-
sectional data from the general population and from
THAOS baseline visit (including both carriers and symp-
tomatic patients) were pooled together, with the object-
ive to assess the effect of the disease across quality of life
dimensions and to estimate the disease impact on utility.
In the second analysis, longitudinal data from symptom-
atic patients was used to explore possible prognostic fac-
tors associated with HRQoL. Pearson’s chi-square test
was used to compare categorical variables between
groups and Wilcoxon rank-sum test was used for com-
parisons of continuous variables. Crude utilities values
(not based on models), standard errors (SE) and 95%
confidence intervals (CI) were estimated.
In the first analysis, the independent variables included
demographic covariates (age, sex and educational attain-
ment) and two models were fitted to the cross-sectional
data. First, for each EQ-5D dimension, a dependent bin-
ary variable was created to define the absence (severity
level 1) or presence (severity level 2 or 3) of health prob-
lems. A 5-equation multivariate probit simultaneous
model (model 1) was used to estimate several correlated
binary outcomes jointly and to identify factors associated
with the probability of reporting health problems among
all EQ-5D dimensions. Second, the utility complement
(disutility; defined as 1 − EQ-5D utility index score) was
used as dependent variable in a model aiming to esti-
mate the disease impact on utility (model 2). Different
generalized linear models (GLM) were specified and the
GLM with the best distribution and link function (as
assessed through the Akaike and Bayesian information
criteria) was used.
In the second analysis, the independent variables in-
cluded demographic covariates, as well as clinical char-
acteristics comprising age of onset (late (≥50 years) and
early-onset patients), disease duration (defined as time
since disease symptoms onset measured at baseline, i.e.,
at enrollment in THAOS or first EQ-5D response),
treatment (untreated, treated with LTx or tafamidis) and
disease stage. At study cut-off date there were no pa-
tients on other treatments participating on THAOS. Dis-
ease stage was captured in THAOS by the modified
Polyneuropathy Disability (mPND) score that categorizes
patients into five stages (I,II, IIIa, IIIb, IV) based on mo-
bility status (walking without difficulty, walking with
some difficulty, walking with 1 support, walking with 2
supports, not ambulatory) [26]. Patients with confirmed
diagnosis, but lacking polyneuropathy symptoms were
categorised as mPND stage I. The utility complement
was used as dependent variable to fit a population-
averaged panel-data (model 3) through a generalized es-
timating equations (GEE) model, accounting for the lon-
gitudinal features of patient’s dataset. To measure
treatment effect adequately, patients with only one visit
were excluded from this analysis. The GEE model with
the best distribution and link function (as assessed
through the Quasilikelihood under the Independence
model) was used. We conducted a further analysis, using
the same model, where mPND was mapped into Cou-
tinho clinical stages [7] because Coutinho hATTR-PN
stages is still the most common classification used in
clinical practice. For this mapping, we used the following
cut-offs: stage 1, if mPND ≤II or patients with confirmed
diagnosis but lacking polyneuropathy symptoms; stage 2,
if mPND = IIIa or IIIb; and stage 3, if mPND = IV.
Additionally, an exploratory analysis was conducted to
analyse possible differences in utility between the two
Portuguese referral centers (Lisbon or Porto).
All statistical analysis was performed using Stata Stat-
istical Software: Release 15.0 (StataCorp LLC, College
Station, TX). The threshold for statistical significance
was set at α = 0.05.
Results
Study sample
The general population dataset included 1500 Portu-
guese subjects. THAOS EQ-5D-3L data were available
from 621 asymptomatic carriers and 733 symptomatic
patients. A total of 4 non-Val30Met subjects and 5 sub-
jects with incomplete EQ-5D-3L data were excluded
from the analysis. Table 1 shows the main baseline char-
acteristics of the three groups.
The proportion of male, age and educational attain-
ment differed between groups (p < 0.001). As expected,
median age was lower among asymptomatic carriers and
patients, as the disease affects mainly young adulthood
[3]. Asymptomatic carriers were mostly female, younger
and with higher level of educational attainment, as com-
pared with general population subjects and patients.
EQ-5D dimensions
Figure 1 shows the crude distribution of health problems
in the three groups as assessed with the EQ-5D. Among
hATTR-PN patients, the EQ-5D dimensions more fre-
quently compromised were pain/discomfort (70% of the
patients), anxiety/depression (57% of the patients) and
usual activities (44% of the patients) (Fig. 1). Among
asymptomatic carriers, the EQ-5D dimension more fre-
quently compromised was anxiety/depression (39% of
the patients) (Fig. 1).
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Model 1 estimated jointly the probability of reporting
health problems for each EQ-5D dimension allowing for
the fact that these probabilities might vary by group, but
also due to other subject characteristics (e.g. sex, age). In
comparison to the general population, hATTR-PN pa-
tients have their health status severely impaired in all
five EuroQoL dimensions (p < 0.001). An additional
table shows model coefficients in detail (see Add-
itional file 1: Table 1). In comparison to the general
population, asymptomatic carriers reported more fre-
quently anxiety/depression problems, but less pain/
discomfort problems (p < 0.001).
Table 1 Demographic characteristics
General population Asymptomatic Carriersa Symptomatic Patientsa
No. 1500 621 733
Sex
Male, n (%) 711 (47.4) 218 (35.1) 378 (51.6)
Age, years
Mean ± SD 48 ± 18.8 36.1 ± 13.3 42.7 ± 12.6
Median (IQR) 47 (32–64) 33 (26–44) 39 (34–49)
Subjects by age group, n (%)
18–29 322 (21.7) 239 (38.5) 82 (11.2)
30–49 495 (33.3) 280 (45.1) 474 (64.7)
50–69 393 (26.5) 89 (14.3) 143 (19.5)
≥ 70 275 (18.5) 13 (2.1) 34 (4.6)
Educational attainment, n (%)
Low 773 (51.9) 131 (21.3) 294 (40.4)
Medium (secondary) 401 (26.9) 323 (52.6) 321 (44.1)
High (bachelor, master or doctorate) 314 (21.1) 160 (26.1) 113 (15.5)
aCharacteristics at enrollment or first EQ-5D response; SD denotes standard deviation; IQR denotes interquartile range
Fig. 1 Proportion of subjects reporting health problems (severity level 2/3) by EQ-5D dimension
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Utilities
Model 2 estimated the utilities according to the group,
while controlling for other subject characteristics (e.g.
sex, age). The model estimates utility scores with refer-
ence to a base-case subject profile (the reference case is
general population, female, 18–29 years of age with low
educational attainment). Older age, female sex, lower
educational attainment and symptomatic disease were
associated with poorer HRQoL (p < 0.001) (see Add-
itional file 1: Table 2). Overall, no differences in utility
were found between carriers and the general population
(p = 0.209). The utility value for a hATTR-PN patient
was estimated to be 0.51 (SE 0.021), a decrement of 0.27
versus the general population (0.78, SE 0.006). All sex
and age groups of hATTR-PN patients showed a utility
decrement (Table 2).
Model 3 estimated the utilities for health states (mPND
stage) among hATTR-PN patients, while exploring the in-
fluence of demographic and other clinical covariates, and
an interaction between visits and treatment. Table 3
shows the clinical characteristics of hATTR-PN patients
analyzed in the model.
Older age (≥70 years), lower educational attainment,
higher disease duration, not receiving treatment and
higher mPND disease stage were associated with poorer
HRQoL (p < 0.05). Overall expected utility values for un-
treated patients and treated patients was 0.56 (0.012)
and 0.59 (0.009), respectively. In general, a decline in
quality of life was observed among untreated patients
over time (visits) (p < 0.05), while it was found that
treated patients increased/preserved their quality of life
through the years (interaction term treatment/visit, p <
0.05) (see Additional file 1: Figure 1). No differences in
utility was found between genders (p = 0.910) or among
early patients as compared with those with late-onset
disease (p = 0.254). An additional table shows model co-
efficients in detail (see Additional file 1: Table 3). Results
of the exploratory analysis found no difference in utility
between referral centers (p = 0.210).
Figure 2 shows the expected utility values for each dis-
ease mPND stage, documenting a substantial impair-
ment in HRQoL as disease progresses. Similar results
Table 2 Mean utility (SE) in each group, by sex and age group
General Population Carriers Patients
Age
group
Female Male Female Male Female Male
18–29 0.84 (0.014) 0.88 (0.012) 0.86 (0.008) 0.88 (0.007) 0.65 (0.022) 0.71 (0.018)
30–49 0.81 (0.014) 0.84 (0.015) 0.82 (0.009) 0.85 (0.008) 0.56 (0.021) 0.63 (0.016)
50–69 0.65 (0.017) 0.74 (0.018) 0.72 (0.017) 0.76 (0.015) 0.31 (0.041) 0.43 (0.033)
≥70 0.56 (0.025) 0.66 (0.025) 0.64 (0.027) 0.70 (0.024) 0.13 (0.065) 0.28 (0.054)
All 0.78 (0.006) 0.80 (0.009) 0.51 (0.021)
Table 3 hATTR-PN patients clinical characteristics
Characteristics Patients
No. Subjects (no. visits) 733 (2913)
Age at onset, years
Mean ± SD 38.1 ± 12.6
Median (IQR) 34 (29–44)
Late-onset, n (%) 116 (15.8)
Disease duration at THAOS enrolment, years
Mean ± SD 4.5 ± 4.8
Age at diagnosis, years
Mean ± SD 39.4 ± 12.9
Median (IQR) 35 (30–45)
Disease mPND stage, n (%)
stage I 537 (73.3)
stage II 141 (19.2)
stage IIIa 22 (3)
stage IIIb 12 (1.6)
stage IV 21 (2.9)
Disease Coutinho stage, n (%)
stage 1 678 (92.5)
stage 2 34 (4.6)
stage 3 21 (2.9)
Visit, n
1 733
2 641
3 526
4 419
5 298
6 187
7 88
8 16
9 5
Treated, n (%) 637 (86.9)
Clinical characteristics measured at THAOS enrolment or first EQ-5D-3L
response; Treatment variable status measured across follow-up; SD denotes
standard deviation, IQR interquartile range
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were found when disease progression is captured by
Coutinho stages (Fig. 3).
An additional table shows model coefficients in detail
(see Additional file 1: Table 4).
Discussion
Disease rarity can cause uncertainty in estimates [27] that
may reveal to be determinant in health technology
assessment [28–30], such as utility values. In this study, we
aimed to assess the effect of hATTR-PN across HRQoL di-
mensions, in both carriers and patients, to estimate the im-
pact on utility in comparison to the general population, as
well as to explore HRQoL prognostic factors among patients,
including disease progression (clinical stage) and treatment.
The main findings of our study are as follows. First, a
high proportion of hATTR-PN patients have some
Fig. 2 Mean utility (SE), by hATTR-PN mPND disease stage
Fig. 3 Mean utility (SE), by hTTR-PN Coutinho clinical stage
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impairment on each of these HRQoL dimensions: mobil-
ity, self-care, usual activities, pain/discomfort and anx-
iety/depression. Second, although average utility was not
different between asymptomatic carriers and the general
population, the probability of carriers experiencing anx-
iety/depression problems is higher, which is consistent
with the published literature on the psychological conse-
quences of pre-symptomatic genetic testing such as anx-
iety, depression, avoidance/denial of the disease, and
psychological distress [31–34]. This result reinforces the
impact that emotional and psychological factors may
have, not only among patients but also among carriers
of the disease-causing mutation.
Third, interestingly, carriers reported less pain/dis-
comfort problems in comparison to the general popula-
tion, which can be due to a misclassification bias as a
result from inaccurate recall. Although the reasons to
explain this finding remain unclear, possible explana-
tions may be associated with the carrier’s knowledge
from living with relatives with the disease (which experi-
ence pain/discomfort) that may prompt carriers to re-
port less likely these problems and with carrier’s disease
denial. Fourth, average utility among hATTR-PN pa-
tients is about two-thirds of the general population, a
difference higher than values often used to establish a
minimally important difference [35, 36]. This clinically
important difference is observed across all sex and age
groups. As compared with other chronic diseases patients,
hATTR-PN utility (0.51) is lower than utilities for psoria-
sis (0.75) [37], type 2 diabetes mellitus (0.68) [38], heart
failure (0.63) [39] and rheumatoid arthritis (0.62) [40], al-
though higher than for visual impairment condition (0.44)
[41]. Fifth, older age, lower educational attainment, higher
disease duration, not receiving treatment and higher dis-
ease stage were found to be determinants of poorer
HRQoL among hATTR-PN patients, without differences
between genders or between early and late-onset patients.
The HRQoL among untreated patients was found deteri-
orating over time, while treated patients increased and
preserved their HRQoL through the years. Average utility
of late-stage hATTR-PN patient is similar to the value
assumed for the death health state.
Previous studies evaluating HRQoL on patients with
hATTR-PN either excluded patients who were already
non ambulatory or had advanced neurological disability
[17], enrolled a small number of patients at advanced
disease stages (n ≤ 15) [42], lacked a comprehensive ana-
lysis of HRQoL clinical prognostic determinants [20], or
excluded LTx-treated patients [43]. Furthermore, other
methodological aspects from these previous studies may
be debatable, such as applying a specific country EQ-5D
value set to preference-based questionnaires provided by
subjects from different geographies [20]. Nevertheless,
our results are in agreement with these previous studies,
showing HRQoL impairment among hATTR-PN pa-
tients, but not among carriers, in comparison to the gen-
eral population [20], a very low utility value at latter
stages of the disease [42], and a positive treatment effect
on HRQoL patients [43].
The main strength of our patient reported outcome
(PRO) study is the inclusion of over 1300 hATTR-PN
Val30Met patients and asymptomatic carriers, which
were followed prospectively. In addition to provide a
comprehensive analysis of HRQoL among hATTR-PN
patients and carriers, we anticipate that our results are
relevant for the process of health economics technology
assessment. Cost-effectiveness decision analysis usually
requires preference-based HRQoL data (utility values) to
estimate quality-adjusted life-years (QALY). This is of
particular importance for hATTR-PN, because two new
drugs (inotersen and patisiran) have recently received
market authorization in Europe and US for hATTR-PN
[13, 14]. Applying country tariffs to raw EQ-5D response
data from a large longitudinal registry is preferred by
HTA agencies [44] but difficulties remain due to disease
rarity. One of the most challenging decisions that payers
face when adopting an orphan drug is related to the un-
certainty of the HRQoL estimates due to small sample
and poor-quality data.
Our study has some limitations. First, although the
sample showed good variation in demographic and clin-
ical characteristics, it may have been subject to selection
bias due to the observational nature of the study. The
THAOS sample here analyzed represents nearly 57% of
Portuguese hATTR-PN patients followed at the referral
centers during 2016. Nevertheless, this sample was
younger and included more men [6]. Furthermore, our
sample may underrepresent the population of patients at
later disease stages, as those are usually wheelchair/
bedridden and less willing and less likely to participate in
prospective registries. Moreover, small sample sizes in the
later stages can limit the precision of estimated
coefficients for stage differences. Second, all hATTR-PN
patients and carriers had the Val30Met mutation. Al-
though having the same mutation warrant genetic homo-
geneity to our sample, caution is needed in generalize the
results to populations with other TTR mutations and dis-
ease presentations, which are more common in other
geographies [45]. Third, utility scores rely on EQ-5D-3L, a
patient self-reported outcome instrument. Errors inherent
to self-report can seriously bias the estimates. PRO mea-
sures play a key role in patient-centered care research but
the quality of results and the true nature of the associa-
tions depend on the validity of the measures [46]. In this
study, demographic and clinical characteristics were veri-
fied by the referral centers which increase overall data val-
idity. Fourth, for the comparison of HRQoL between the
three groups, we were only able to use cross-sectional
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data. Prospective data was only used for exploring HRQoL
prognostic factors among patients. Nevertheless, the re-
sults found across groups strongly suggest that EQ-5D-3L
is a valid instrument in assessing HRQoL among hATTR-
PN patients.
Conclusions
Due to the small number of people with rare diseases,
there is more uncertainty about the health gains from
treatments and the best way to decrease this uncertainty
is to collect long-term outcomes data, through large pa-
tient’s registries such as THAOS. In the case of hATTR-
PN patients, we can conclude that clinical strategies fo-
cused on quality of life preservation such as close
follow-up of asymptomatic carriers, prompt diagnosis
and adequate and early treatment would largely benefit
patient’s long-term outcomes.
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